The experimental study of the KEYNOTE-042 trial in patients who were randomly preferred to receive pembrolizumab or first-line platinum-based chemotherapy revealed that the individuals who had KRAS G12C mutations had higher PD-L1 tumor proportion scores (TPS) and TMB in comparison to patients who had the KRAS wild-type mutation. Here, KRAS is linked to neoplasm.